Skip to main content

Advertisement

Table 3 Cytotoxicity of compounds 15, 16, 17, 18, 19, 20 and Doxorubicin against hepatocellular carcinoma cell line HePG2

From: Design, synthesis and evaluation of anticancer activity of novel 2-thioxoimidazolidin-4-one derivatives bearing pyrazole, triazole and benzoxazole moieties

Concentration µg/mL Viability (%)/compound
15 16 17 18 19 20 Doxorubicin
500 6.49 4.31 6.78 4.68 3.84 6.91 3.6
250 11.25 11.72 15.93 10.35 9.65 11.76 3.97
125 19.43 18.25 24.85 17.46 13.81 20.95 6.43
62.5 30.61 23.87 34.91 25.72 19.46 32.47 9.68
31.25 39.45 30.64 42.87 32.69 25.83 44.35 16.45
15.6 51.26 38.92 67.29 44.82 32.17 76.97 23.87
7.8 67.18 47.30 83.97 51.96 39.68 89.50 30.69
3.9 84.91 64.59 91.48 64.53 48.54 94.16 37.54
2 92.73 76.28 98.02 72.31 61.83 98.73 42.91
1 96.48 81.49 100 79.48 69.42 100 48.76
0 100 100 100 100 100 100 100